ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $4.60.

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings upgraded shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday.

More ALX Oncology News

Here are the key news stories impacting ALX Oncology this week:

• Positive Sentiment: HC Wainwright raised its 2026 EPS forecast to a loss of $0.55 per share from a loss of $0.59, improving on the current consensus estimate of a $0.61 loss. The firm also lifted its Q3 2026, Q4 2026, and Q1 2027 estimates to losses of $0.13 per share from $0.14.
• Positive Sentiment: The analyst increased its FY2028 EPS forecast to a loss of $0.46 per share from $0.51, suggesting somewhat better long-term cost or operating expectations for ALX Oncology.
• Neutral Sentiment: Despite the improvements, HC Wainwright still expects ALXO to remain unprofitable, forecasting losses of $0.57 per share in FY2027, $0.51 in FY2029, and $0.50 in FY2030. The company’s recent quarterly results also showed a loss, although it exceeded analyst expectations.
• Negative Sentiment: HC Wainwright lowered its FY2027 EPS forecast to a loss of $0.57 from $0.56, its FY2029 estimate to a loss of $0.51 from $0.49, and its FY2030 estimate to a loss of $0.50 from $0.43. It also reduced its Q4 2027 forecast to a loss of $0.15 from $0.13.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXO. Beacon Pointe Advisors LLC acquired a new position in shares of ALX Oncology in the 2nd quarter valued at $26,000. Callan Family Office LLC acquired a new stake in ALX Oncology during the 2nd quarter worth $46,000. The Manufacturers Life Insurance Company bought a new position in ALX Oncology during the second quarter worth about $64,000. Bridgeway Capital Management LLC bought a new position in ALX Oncology during the third quarter worth about $66,000. Finally, AXQ Capital LP acquired a new position in shares of ALX Oncology in the 2nd quarter valued at approximately $84,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Trading Up 2.5%

Shares of ALX Oncology stock opened at $2.04 on Friday. ALX Oncology has a 52-week low of $0.96 and a 52-week high of $2.66. The firm has a market capitalization of $282.09 million, a PE ratio of -1.81 and a beta of 0.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.71 and a quick ratio of 9.71. The company’s fifty day moving average price is $1.96 and its two-hundred day moving average price is $1.97.

ALX Oncology (NASDAQ:ALXO) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, analysts expect that ALX Oncology will post -0.6 EPS for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.